AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The IL-23 inhibitor risankizumab proved to be safe and efficacious after 52 weeks of treatment in patients with ...

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable ...

Most patients with moderate to severe CD who did not initially respond to risankizumab achieved clinical response after extension. Delayed responders also demonstrated clinical and endoscopic ...